Full Press Release Details
Bioscience Bioscience Obesity Nasdaq: SKYE © 2026 Skye Bioscience. All Rights Reserved. All Primers Perspectives Progress Press Unlocking Solutions to Deliver Higher Doses Date published: January 4, 2026 9:05 pm PST Share
SKYE Neutral Sentiment
Unlocking Solutions to Deliver Higher Doses
Key Takeaway: The article discusses Skye Bioscience's efforts to develop solutions for delivering higher doses of treatments. It highlights the importance of addressing dosing challenges in bioscience, particularly in the context of obesity. The publication date indicates a recent focus on advancements in this area.
Price reaction · baseline $0.8782 (2026-01-02 close) · 3 other SKYE headline(s) in the window, move may be shared
day 0 close
-2.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity